Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT07330778

A Study of CDX-622 in Participants With Mild to Moderate Asthma

Led by Celldex Therapeutics · Updated on 2026-04-01

12

Participants Needed

2

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

CONDITIONS

Official Title

A Study of CDX-622 in Participants With Mild to Moderate Asthma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females, 18 years of age or older
  • Diagnosis of mild to moderate asthma for at least 12 months
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) at least 70% of predicted normal
  • Airway reversibility of at least 12% and 200 mL improvement in FEV1
  • Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
  • Willing and able to comply with all study requirements and procedures
Not Eligible

You will not qualify if you...

  • Females who are pregnant or nursing
  • Pulmonary disease other than asthma
  • Systemic diseases with elevated eosinophils other than asthma
  • Hospitalization or use of oral corticosteroids due to asthma within the past 6 months
  • History of needing ventilator support due to asthma
  • Current nasal polyps
  • Severe or uncontrolled asthma
  • History of smoking or vaping within the past 12 months
  • Tuberculosis, hepatitis B or C virus, or HIV infection
  • Use of immunomodulating biologic therapies within the past 3 months
  • Prior treatment with TSLP or KIT inhibitors such as tezepelumab or briquilimab
  • Additional protocol defined inclusion and exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

2

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

Loading map...

Research Team

C

Celldex Therapeutics

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here